SteadyTeq Archives - PharmaDeviceNews

Editorial infographic highlighting Medincell’s second FDA-approved drug, Weltruza, featuring an injectable medicine, FDA approval symbol, U.S. launch map and graphics illustrating clinical evidence, royalty potential and commercial outlook.

Can Weltruza become Medincell’s next growth driver after Uzedy commercial success?

by Pallavi Madhiraju
October 11, 2026
0 Comments

Medincell gains a second FDA-approved drug as Teva prepares Weltruza's U.S. launch. See the clinical evidence, royalties and commercial outlook.

Infographic showing FDA approval of Teva’s Weltruza, a monthly subcutaneous olanzapine that requires no loading doses, oral supplementation or post-injection monitoring.

Pharma & Biotech

Teva wins FDA approval for Weltruza as monthly olanzapine changes schizophrenia LAI equation

by Pallavi Madhiraju
October 10, 2026
0 Comments

Teva’s Weltruza wins FDA approval as a monthly subcutaneous olanzapine without loading doses, oral supplementation or post-injection monitoring.

Teva Pharmaceutical Industries’ once-monthly TEV-’749 could make long-acting olanzapine more practical if FDA review supports use without the three-hour post-injection monitoring required for existing olanzapine depot therapy. Representative image.

Features & Analysis

Teva saw no PDSS across 3,470 injections. Could TEV-’749 finally make long-acting olanzapine practical?

by Pallavi Madhiraju
September 20, 2026
0 Comments

Teva Pharmaceutical Industries has reported new long-term data for once-monthly subcutaneous TEV-’749 ahead of an expected fourth-quarter FDA decision. Its competitive proposition is not a new antipsychotic mechanism, but an attempt to combine established olanzapine efficacy with long-acting dosing without the post-injection monitoring burden that has constrained the existing olanzapine depot.